Harvard Bioscience (HBIO) Stock Price

Harvard Bioscience Price

NASDAQ·CLOSED
6.40USD+0.13 (+2.05 %)
Market closed

Revenue has compounded at 0.7% per year over the past 19 years to 86.55 M USD. Earnings per share have grown at 4.9% per year over the last 6 years. Harvard Bioscience's net margin stands at -65.5%, down from -0.2% several years earlier. Analysts set a median price target of 2.04 USD, implying 68.1% below the current price. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 68% above its 52-week low.

Harvard Bioscience stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Harvard Bioscience over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Harvard Bioscience stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Harvard Bioscience's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Harvard Bioscience Stock Price History
DateHarvard Bioscience Price
8/5/20266.40 USD
8/4/20266.27 USD
8/3/20266.31 USD
7/31/20266.10 USD
7/30/20266.09 USD
7/29/20266.10 USD
7/27/20266.11 USD
7/23/20266.19 USD
7/22/20266.13 USD
7/21/20266.04 USD
7/20/20266.11 USD
7/17/20266.23 USD
7/16/20265.95 USD
7/15/20266.03 USD
7/14/20265.93 USD
7/13/20266.12 USD
7/10/20266.14 USD
7/9/20266.23 USD
7/8/20266.33 USD
7/7/20266.63 USD
7/6/20266.15 USD
7/2/20266.15 USD
7/1/20266.05 USD
6/30/20266.15 USD
6/29/20266.13 USD
6/26/20266.04 USD
6/25/20265.96 USD
6/24/20266.08 USD
6/23/20266.01 USD
6/22/20265.87 USD
6/18/20265.87 USD
6/17/20266.00 USD
6/16/20265.95 USD
6/15/20265.99 USD
6/12/20266.08 USD
6/11/20266.64 USD
6/10/20266.20 USD
6/9/20266.04 USD
6/8/20266.01 USD
6/5/20266.20 USD
6/4/20266.48 USD
6/3/20266.50 USD
6/2/20266.46 USD
6/1/20266.40 USD
5/29/20265.88 USD
5/28/20265.95 USD
5/27/20265.78 USD
5/26/20265.68 USD
5/22/20265.59 USD
5/21/20265.52 USD
5/20/20265.40 USD
5/19/20265.01 USD
5/18/20265.00 USD
5/15/20265.25 USD
5/14/20265.52 USD
5/13/20265.57 USD
5/12/20265.41 USD
5/11/20266.84 USD
5/8/20266.90 USD
5/7/20266.79 USD
5/6/20267.24 USD
5/5/20266.63 USD
5/4/20266.40 USD
4/22/20266.69 USD
4/21/20266.56 USD
4/20/20266.99 USD
4/17/20266.13 USD
4/16/20265.91 USD
4/15/20265.74 USD
4/14/20264.91 USD
4/13/20264.66 USD
4/10/20264.31 USD
4/9/20265.37 USD
4/8/20265.55 USD
4/7/20265.40 USD
4/6/20265.53 USD
4/2/20265.20 USD
4/1/20265.09 USD
3/31/20264.87 USD
3/30/20264.66 USD
3/27/20264.87 USD
3/26/20265.07 USD
3/25/20265.13 USD
3/24/20265.13 USD
3/23/20265.34 USD
3/20/20265.28 USD
3/19/20265.60 USD
3/18/20264.88 USD
3/17/20264.91 USD
3/16/20265.14 USD
3/13/20264.70 USD
3/12/20264.90 USD
3/11/20265.10 USD
3/10/20265.30 USD
3/9/20264.90 USD
3/6/20265.50 USD
3/5/20265.71 USD
3/4/20265.74 USD
3/3/20265.66 USD
3/2/20265.91 USD
2/27/20266.14 USD
2/26/20266.01 USD
2/25/20266.00 USD
2/24/20265.81 USD
2/23/20265.70 USD
2/20/20265.83 USD
2/19/20265.86 USD
2/18/20265.90 USD
2/17/20265.97 USD
2/16/20266.00 USD
2/13/20265.55 USD
2/12/20265.50 USD
2/11/20265.60 USD
2/10/20265.40 USD
2/9/20266.00 USD
2/8/20265.30 USD
2/6/20264.95 USD
2/5/20265.00 USD
2/4/20264.70 USD
2/3/20265.10 USD
2/2/20265.00 USD
2/1/20265.00 USD
1/30/20265.01 USD
1/29/20265.00 USD
1/28/20265.40 USD
1/27/20265.70 USD
1/26/20265.90 USD
1/25/20265.80 USD
1/23/20265.92 USD
1/22/20265.90 USD
1/21/20266.20 USD
1/20/20265.90 USD
1/19/20265.80 USD
1/16/20265.87 USD
1/15/20265.90 USD
1/14/20265.80 USD
1/13/20265.70 USD
1/12/20265.90 USD
1/11/20266.20 USD
1/9/20266.30 USD
1/8/20266.30 USD
1/7/20266.50 USD
1/6/20266.70 USD
1/5/20266.90 USD
1/4/20266.80 USD
1/2/20266.52 USD
1/1/20266.50 USD
12/31/20256.69 USD
12/30/20256.70 USD
12/29/20256.60 USD
12/28/20256.60 USD
12/26/20257.02 USD
12/25/20257.00 USD
12/24/20257.25 USD
12/23/20257.30 USD
12/22/20257.20 USD
12/21/20257.50 USD
12/19/20257.54 USD
12/18/20257.50 USD
12/17/20257.70 USD
12/16/20257.90 USD
12/15/20257.00 USD
12/14/20257.00 USD
12/12/20257.41 USD
12/11/20257.40 USD
12/10/20257.40 USD
12/9/20257.60 USD
12/8/20257.20 USD
12/7/20257.60 USD
12/5/20257.58 USD
12/4/20257.60 USD
12/3/20257.20 USD
12/2/20257.30 USD
12/1/20257.20 USD
11/30/20257.70 USD
11/28/20257.61 USD
11/27/20257.60 USD
11/26/20257.49 USD
11/25/20257.50 USD
11/24/20257.40 USD
11/23/20256.40 USD
11/21/20256.35 USD
11/20/20256.30 USD
11/19/20255.60 USD
11/18/20256.20 USD
11/17/20256.40 USD
11/16/20256.70 USD
11/14/20256.60 USD
11/13/20256.60 USD
11/12/20255.80 USD
11/11/20256.20 USD
11/10/20256.10 USD
11/9/20255.80 USD
11/7/20255.43 USD
11/6/20255.40 USD
11/5/20255.50 USD
11/4/20255.90 USD
11/3/20256.20 USD
11/2/20255.70 USD
10/31/20255.17 USD
10/30/20255.20 USD
10/29/20256.30 USD
10/28/20254.50 USD
10/27/20254.00 USD
10/26/20254.00 USD
10/23/20254.10 USD
10/22/20254.00 USD
10/21/20254.00 USD
10/20/20254.10 USD
10/19/20254.00 USD
10/16/20253.80 USD
10/15/20254.00 USD
10/14/20254.20 USD
10/13/20254.20 USD
10/12/20254.20 USD
10/9/20254.20 USD
10/8/20254.40 USD
10/7/20254.40 USD
10/6/20254.40 USD
10/5/20254.40 USD
10/2/20254.50 USD
10/1/20254.60 USD
9/30/20254.50 USD
9/29/20254.40 USD
9/28/20254.40 USD
9/25/20254.40 USD
9/24/20254.40 USD
9/23/20254.50 USD
9/22/20254.60 USD
9/21/20254.80 USD
9/18/20254.70 USD
9/17/20254.80 USD
9/16/20254.70 USD
9/15/20254.80 USD
9/14/20254.40 USD
9/11/20254.40 USD
9/10/20254.40 USD
9/9/20254.50 USD
9/8/20254.40 USD
9/7/20254.50 USD
9/4/20254.80 USD
9/3/20254.70 USD
9/2/20254.70 USD
9/1/20254.90 USD
8/28/20255.00 USD
8/27/20255.20 USD
8/26/20255.30 USD
8/25/20255.40 USD
8/24/20255.00 USD
8/21/20254.90 USD
8/20/20254.80 USD
8/19/20254.70 USD
8/18/20254.90 USD
8/17/20255.00 USD
8/14/20255.30 USD
8/13/20254.90 USD
8/12/20255.00 USD
8/11/20254.80 USD
8/10/20254.80 USD
8/7/20255.30 USD
8/6/20255.10 USD
Access this data via the Eulerpool API

Harvard Bioscience Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
118.90 M USD
2.07 M USD
-288,000.00 USD
Jan 1, 2022
113.34 M USD
-6.63 M USD
-9.52 M USD
Jan 1, 2023
112.25 M USD
1.89 M USD
-3.42 M USD
Jan 1, 2024
94.14 M USD
-6.21 M USD
-12.41 M USD
Jan 1, 2025
86.55 M USD
-629,000.00 USD
-56.70 M USD
Jan 1, 2026 (e)
88.60 M USD
-13.00 M USD
-31.30 M USD
Jan 1, 2027 (e)
94.20 M USD
-13.82 M USD
19.68 M USD
Jan 1, 2028 (e)
86.50 M USD
-12.69 M USD
0.00 USD

Harvard Bioscience Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 6, 2026, 4:19 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
105.00108.00108.00104.00101.00120.00116.00102.00118.00113.00112.0094.0086.0088.0094.0086.00
-5.412.86-3.70-2.8818.81-3.33-12.0715.69-4.24-0.88-16.07-8.512.336.82-8.51
44.7645.3744.4446.1546.5352.5055.1756.8656.7853.1058.9357.4552.3352.3352.3352.33
47.0049.0048.0048.0047.0063.0064.0058.0067.0060.0066.0054.0045.0046.0549.1945.00
1.006.00-1.00-2.00-1.002.00-6.001.00-6.00-12.00-13.00-12.00
0.955.56-0.93-1.92-0.991.69-5.310.89-6.38-13.64-13.83-13.95
-1.002.00-19.00-4.00-3.00-4.00-7.00-9.00-3.00-12.00-56.00-31.0019.00
-150.00-300.00-1,050.00-78.9533.3375.00-66.67300.00366.67-44.64-161.29
3.243.2433.953.443.613.733.803.894.344.214.274.354.444.444.444.44
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Harvard Bioscience generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Harvard Bioscience retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Harvard Bioscience's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Harvard Bioscience has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Harvard Bioscience's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Harvard Bioscience stock margins

The Harvard Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Harvard Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Harvard Bioscience.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
56.90 %
1.74 %
-0.24 %
Jan 1, 2022
53.66 %
-5.85 %
-8.40 %
Jan 1, 2023
58.86 %
1.69 %
-3.04 %
Jan 1, 2024
58.18 %
-6.60 %
-13.18 %
Jan 1, 2025
53.01 %
-0.73 %
-65.51 %
Jan 1, 2026 (e)
53.01 %
-14.67 %
-35.33 %
Jan 1, 2027 (e)
53.01 %
-14.67 %
20.89 %
Jan 1, 2028 (e)
53.01 %
-14.67 %
0.00 %

Harvard Bioscience Stock Revenue, EBIT, Earnings per Share

The Harvard Bioscience earnings per share therefore indicates how much revenue Harvard Bioscience has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
274.15 USD
4.76 USD
-0.66 USD
Jan 1, 2022
269.19 USD
-15.75 USD
-22.60 USD
Jan 1, 2023
262.82 USD
4.43 USD
-8.00 USD
Jan 1, 2024
216.21 USD
-14.27 USD
-28.49 USD
Jan 1, 2025
194.97 USD
-1.42 USD
-127.73 USD
Jan 1, 2026 (e)
19.81 USD
-29.28 USD
-7.00 USD
Jan 1, 2027 (e)
21.06 USD
-31.13 USD
4.40 USD
Jan 1, 2028 (e)
19.34 USD
-28.59 USD
0.00 USD

Harvard Bioscience business model & stock analysis

Harvard Bioscience Inc was founded in 1901 and is headquartered in Holliston, Massachusetts. The company is a global leader in providing instruments, technologies, and complete systems for science and research. Harvard Bioscience has established itself as one of the leading providers of products and solutions in the fields of life sciences and health research with over 100 years of industry experience. The business model of Harvard Bioscience is focused on delivering high-quality products and solutions for research needs. The company is divided into three business segments: Life Science Research Products, Preclinical Surgical Products, and Analytical Instruments. These business segments offer a variety of products, such as instruments for cell and molecular research, gene expression analysis devices, surgical instruments, and instruments for electrophysiology. The Life Science Research segment includes the business units Harvard Apparatus, Molecular Devices, and Denville Scientific. Harvard Apparatus provides instruments for cell and molecular research, physiological instruments, and animal model systems. Molecular Devices specializes in instrumental analysis methods for cell and molecular research. Denville Scientific is a leading supplier of products for cell and molecular biology, including materials for gene and protein expression and cell culture techniques. In the Preclinical Surgical Products segment, Harvard Bioscience operates with the company Hugo Sachs Elektronik. Surgical instruments and complete systems for preclinical research are offered here. These products are popular among scientists worldwide as they have been developed for conducting research with animal models. Analytical Instruments is the segment where the company operates joint ventures to develop instruments for physical, material, and life science research. In this segment, Harvard Bioscience is primarily involved in the joint venture Wasatch Microfluidics, alongside Agilent Technologies, which specializes in the development of instruments for life sciences and biotechnology. As a provider of science and research-related instruments and devices, Harvard Bioscience has a wide range of products to help researchers and scientists enhance their work more effectively. Some of the most popular products from Harvard Bioscience include tissue processing systems, neuroprotection applications, animal model holders, and electrophysiology platforms. Harvard Bioscience also offers a range of products for quality assurance and environmental protection, such as cleanroom and protection devices for material preparation and sterilization. Overall, Harvard Bioscience Inc has an excellent reputation in the industry and is one of the world's leading companies for scientific and research-related products and services. The company constantly strives to improve its products and services and adapts to the needs of its customers. It relies on innovation and continuously works to develop and implement new technologies to meet the demands of the scientific world.

Harvard Bioscience SWOT Analysis

Strengths

Harvard Bioscience Inc has established itself as a leading player in the bioscience industry, with a wealth of knowledge and experience in developing and manufacturing innovative scientific instruments and tools. This expertise gives the company a competitive advantage in understanding the needs of its target market and providing tailored solutions.

The company offers a wide range of high-quality products, including laboratory equipment, consumables, and specialized research tools. Harvard Bioscience’s diverse product portfolio enables it to serve various segments within the bioscience industry, catering to different customer requirements and maximizing revenue potential.

Harvard Bioscience Inc invests significantly in research and development activities to drive product innovation and stay ahead of the market. Its strong R&D capabilities enable the company to introduce cutting-edge technologies and solutions that meet emerging customer demands, enhancing its competitive position.

Weaknesses

A significant portion of Harvard Bioscience's revenue comes from a few key customers. This dependency poses a risk to the company as any loss of these customers or decline in their orders could have a substantial impact on its financial performance. Diversifying the customer base would help mitigate this vulnerability.

While Harvard Bioscience has a global customer base, its geographic presence remains relatively limited. This concentration exposes the company to regional economic factors and regulatory changes in specific markets. Expanding into new geographies would reduce the company's dependence on any single market and create additional growth opportunities.

Opportunities

The global bioscience industry is experiencing a rapid expansion, driven by increased investments in research and development activities in various sectors, including pharmaceuticals, biotechnology, and academia. This growth presents Harvard Bioscience with opportunities to capitalize on rising demand for its research tools and equipment.

The continuous advancements in fields such as genomics, proteomics, and molecular biology provide Harvard Bioscience with an opportunity to develop and introduce innovative products that cater to these evolving research needs. By staying at the forefront of technological breakthroughs, the company can gain a competitive edge.

Threats

The bioscience industry is intensely competitive, with numerous companies vying for market share. Harvard Bioscience faces competition from both established players and emerging startups. This competitive landscape puts pressure on pricing, requires continuous innovation, and increases the challenges of maintaining market leadership.

The bioscience industry is subject to strict regulations and compliance requirements, which can create barriers to entry and affect product development timelines. Harvard Bioscience must remain compliant with these regulations to ensure the quality and safety of its products while also navigating the associated costs and complexities.

The global economic uncertainty and market volatility can impact Harvard Bioscience's business, as spending on research and development activities may fluctuate during economic downturns. The company must be prepared to adapt its strategies and manage its resources effectively in response to changing market conditions.

Harvard Bioscience Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Harvard Bioscience Employees
Details
Date
Harvard Bioscience Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Harvard Bioscience Segments

Harvard Bioscience Revenue by Segment (1/2)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Instruments, equipment and accessories
Instruments, Equipment, Software, and Accessories
Service, Maintenance, and Warranty Contracts
Service, maintenance and warranty contracts
Details
Date
Instruments, equipment and accessories
Instruments, Equipment, Software, and Accessories
Service, Maintenance, and Warranty Contracts
Service, maintenance and warranty contracts
Jan 1, 2012
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Harvard Bioscience Revenue by Segment (2/2)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

LSRT Reportable Segment
Rmd Reportable Segment
Unallocated
Details
Date
LSRT Reportable Segment
Rmd Reportable Segment
Unallocated
Jan 1, 2012
111.17 M USD
0.00 USD
0.00 USD

Harvard Bioscience Revenue by Region

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Total
Segment, Geographical, United States
United States
Europe
EMEA
Asia
Segment, Geographical, United Kingdom
Greater China
Segment, Geographical, Germany
International
CHINA
Asia, Other
Americas, Other
Details
Date
Total
Segment, Geographical, United States
United States
Europe
EMEA
Asia
Segment, Geographical, United Kingdom
Greater China
Segment, Geographical, Germany
International
CHINA
Asia, Other
Americas, Other
Jan 1, 2017
101.88 M USD
66.20 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
15.04 M USD
0.00 USD
11.16 M USD
9.48 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
79.61 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
13.69 M USD
0.00 USD
13.19 M USD
8.57 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
42.05 M USD
29.94 M USD
0.00 USD
23.88 M USD
0.00 USD
0.00 USD
0.00 USD
6.22 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
49.83 M USD
35.77 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
8.49 M USD
24.82 M USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
49.91 M USD
30.69 M USD
0.00 USD
0.00 USD
0.00 USD
16.39 M USD
0.00 USD
16.34 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
48.21 M USD
32.80 M USD
0.00 USD
0.00 USD
0.00 USD
18.49 M USD
0.00 USD
12.76 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
41.74 M USD
0.00 USD
28.41 M USD
0.00 USD
0.00 USD
13.30 M USD
0.00 USD
0.00 USD
0.00 USD
7.10 M USD
3.60 M USD
Jan 1, 2025
0.00 USD
0.00 USD
38.97 M USD
0.00 USD
26.71 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
10.97 M USD
6.68 M USD
3.23 M USD

Harvard Bioscience Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Harvard Bioscience historical P/E ratio, EBIT multiple, and P/S ratio

Harvard Bioscience annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Harvard Bioscience shares outstanding

The number of shares of Harvard Bioscience was 443,910 in 2025. This indicates how many shares Harvard Bioscience is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
433,720.00 Stocks
Jan 1, 2022
421,020.00 Stocks
Jan 1, 2023
427,100.00 Stocks
Jan 1, 2024
435,380.00 Stocks
Jan 1, 2025
443,910.00 Stocks
Jan 1, 2026 (e)
443,910.00 Stocks
Jan 1, 2027 (e)
443,910.00 Stocks
Jan 1, 2028 (e)
443,910.00 Stocks

Harvard Bioscience stock splits

In Harvard Bioscience's history, there have been no stock splits.

Current Harvard Bioscience forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
75.00 % (6)
Hold
25.00 % (2)
Sell
0.00 % (0)
12M Price Target
2.04
Last Price
6.40
Currency
USD
12M Return Potential
-68.13 %
LTM Return
0 %

Harvard Bioscience Analyst Rating Actions

DateFirmActionRatingReliability
3/16/2026
Benchmark
Benchmark
MaintainedSpeculative Buy71
3/13/2026
Benchmark
Benchmark
MaintainedSpeculative Buy71
9/10/2025
Benchmark
Benchmark
MaintainedSpeculative Buy71
5/13/2025
Benchmark
Benchmark
MaintainedSpeculative Buy71
4/9/2025
Keybanc
Keybanc
DowngradeOverweightSector Weight49
4/8/2025
Keybanc
Keybanc
DowngradeOverweightSector Weight49
3/24/2025
Benchmark
Benchmark
MaintainedSpeculative Buy71
6/22/2023
Benchmark
Benchmark
MaintainedSpeculative Buy71
4/26/2023
Keybanc
Keybanc
MaintainedOverweight49
4/26/2023
Benchmark
Benchmark
MaintainedBuy71

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Harvard Bioscience Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/11/2026-0.21USD-21.88 MUSD-2026 Q2
5/12/2026-0.63USD-21.62 MUSD-2026 Q1
3/12/20260.04USD-23.56 MUSD-2025 Q4
4/23/20240.05USD-29.89 MUSD-2024 Q1
3/7/20240.06USD-29.99 MUSD-2023 Q4
11/6/20230.06USD-29.88 MUSD-2023 Q3
8/1/20230.07USD-30.93 MUSD-2023 Q2
5/2/20230.04USD-29.38 MUSD-2023 Q1
3/6/20230.03USD-30.79 MUSD-2022 Q4
11/8/20220.07USD-29.32 MUSD-2022 Q3

EESG©

Eulerpool ESG Scorecard© for the Harvard Bioscience stock

12/100
12
Environment
17
Social
6
Governance
E

Environment

20
Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Harvard Bioscience shareholder structure

% Name
9.05084%
AMH Equity, Ltd.
AMH Equity, Ltd.
4.78779%
Harvey Partners, LLC
Harvey Partners, LLC
4.14555%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
3.66111%
Green (James W)
Green (James W)
3.35758%
Granahan Investment Management, LLC
Granahan Investment Management, LLC
2.51845%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
...

Harvard Bioscience Beneficial Ownership Filings (SEC 13D/G)

Free Float
77.7%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
15.97%
William Snider
William Snider
SEC ↗
15.57%
BroadOak Capital Partners, LLC
BroadOak Capital Partners, LLC
SEC ↗
15.34%
BroadOak Income Fund, L.P.
BroadOak Income Fund, L.P.
SEC ↗
15.00%
Abigail P. Johnson
Abigail P. Johnson
SEC ↗
13.93%
Chancey Graziano
Chancey Graziano
SEC ↗
13.29%
Mathew P. Arens
Mathew P. Arens
SEC ↗
13.29%
First Light Asset Management, LLC
First Light Asset Management, LLC
SEC ↗
12.16%
Matthew P. Arens
Matthew P. Arens
SEC ↗
7.84%
B. Riley Asset Management LLC
B. Riley Asset Management LLC
SEC ↗
7.26%
Weber Capital Management, LLC
Weber Capital Management, LLC
SEC ↗

Harvard Bioscience Executives and Management Board

7 members · avg. age 55 · 14 % women

Management

JD

Mr. John Duke (54)

President, Chief Executive Officer, Director · since 2025

MF

Mr. Mark Frost (62)

Interim Chief Financial Officer, Treasurer

SM

Mr. Sandy Martin

Investor Relations · since 2024

Board of Directors

RG

Mr. Robert Gagnon (51)

Independent Director · since 2013

598,505.00 USD
KE

Ms. Katherine Eade (51)

Lead Independent Director

223,000.00 USD
SD

Mr. Stephen DeNelsky (57)

Director

RB

Mr. Robert Benson

Independent Director

Frequently asked questions about Harvard Bioscience

The business model of Harvard Bioscience Inc is focused on providing innovative tools and solutions to life science researchers. The company specializes in developing and manufacturing scientific instruments, systems, and lab supplies that are used in drug discovery, disease research, and other biomedical applications. These products cater to a wide range of research fields, including cell biology, neurobiology, stem cell research, and physiology. Harvard Bioscience Inc aims to support scientists and enhance their research capabilities by delivering high-quality products that enable efficient and accurate experimentation.

Harvard Bioscience Inc is primarily active in the life sciences industry.

The main competitors of Harvard Bioscience Inc in the market include companies such as Thermo Fisher Scientific, Bio-Rad Laboratories, and PerkinElmer Inc. These companies operate in the life sciences and biotechnology industries, offering a range of products and solutions that compete with Harvard Bioscience Inc's offerings. By providing innovative scientific instruments, tools, and services, these competitors create a competitive landscape within the market. Harvard Bioscience Inc continually faces the challenge of distinguishing its products and maintaining a competitive edge against these major players in the industry.

Harvard Bioscience Inc is a leading global developer, manufacturer, and marketer of specialized products and technologies that advance life science research. Established in 1901, the company has a rich history of innovation and has been at the forefront of scientific advancements. With a focus on providing cutting-edge tools and solutions, Harvard Bioscience Inc has become a trusted partner for researchers and scientists worldwide. Their dedication to delivering high-quality products and services has enabled them to establish a strong presence in the life science industry. Today, Harvard Bioscience Inc continues to drive innovation and shape the future of scientific discovery.

Harvard Bioscience Inc has achieved several significant milestones. The company successfully expanded its product portfolio and strengthened its global presence through strategic acquisitions. They developed innovative technologies and solutions, enhancing their position as a leading provider of scientific instruments. Harvard Bioscience Inc also established collaborations with renowned research institutions and industry partners, fostering scientific advancements and knowledge sharing. The company's relentless commitment to research and development enabled them to introduce groundbreaking products that revolutionized various scientific disciplines. Harvard Bioscience Inc's commitment to excellence and continuous innovation has propelled them to become a trusted name in the scientific community.

Harvard Bioscience Inc primarily operates in the United States, with headquarters in Holliston, Massachusetts. The company also has a presence in Canada, Europe, and Asia, serving customers globally. With a focus on providing advanced tools and solutions for life science research, Harvard Bioscience Inc has established itself as a leading provider of innovative products and services in the field.

Harvard Bioscience Inc represents a set of core values and a strong corporate philosophy. The company is committed to providing innovative solutions for life science research and advancing scientific discovery. Harvard Bioscience Inc prioritizes integrity, collaboration, and excellence in every aspect of its operations. With a focus on customer satisfaction, the company strives to deliver cutting-edge technologies and exceptional service to researchers worldwide. Through its dedication to promoting scientific advancement and improving the understanding of life sciences, Harvard Bioscience Inc has established itself as a trusted and reliable partner in the research community.

Analysts currently set an average price target of 2.04 USD for the Harvard Bioscience stock (median: 2.04 USD), implying -68.1 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the Harvard Bioscience stock: 6 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Harvard Bioscience to generate revenue of 88.60 M USD and earnings per share of -70.52 USD.

Converted at the current exchange rate, the Harvard Bioscience share trades at 5.54 EUR (6.40 USD).

The Harvard Bioscience share (HBIO) is listed on 4 stock exchanges, including: NASDAQ (HBIO), Frankfurt (HBI.F), München (HBI.MU), Düsseldorf (HBI.DU).

Harvard Bioscience Inc is a globally operating company specializing in the sale of scientific instruments and devices for the life sciences. The company is divided into three business segments: Life Science Research, Analytical Instruments, and Bioscience Tools. In the Life Science Research segment, Harvard Bioscience offers a wide range of instruments for the study of cells, tissues, and organs. This includes devices for cell culture, DNA transfection, microinjection, and cell monitoring. Products for tissue research include cell slicers, tissue homogenizers and disruptors, as well as sample manipulation devices. Harvard Bioscience also offers organ perfusion systems, organ baths, and organ isolation devices for organ research. The Analytical Instruments segment focuses on instruments for the analysis of biological samples. This includes pH meters, conductivity meters, pipettes, density meters, and osmometers. The Bioscience Tools segment offers a broad portfolio of tools and consumables for the life sciences. This includes micro pipettes, microinjection needles, cell culture plates, and PCR tubes. A key concept of Harvard Bioscience is the high quality of its products. Most instruments and devices are developed and manufactured in their own production facilities. The company emphasizes strict quality testing and control, as well as compliance with international norms and standards. Harvard Bioscience sells its products worldwide through a network of distribution partners and direct sales channels. The majority of customers are research institutes, universities, biotechnology and pharmaceutical companies, as well as government organizations. The company works closely with its customers and partners to customize products to meet their needs and fulfill specific requirements. A key growth strategy of Harvard Bioscience is continuous innovation and development of its products. The company invests a significant portion of its revenue in research and development each year. By acquiring companies that develop innovative biotechnological technologies, the company aims to strengthen its strong position in the industry and expand its presence in the international market. Overall, the business model of Harvard Bioscience is focused on providing high-quality scientific instruments and technologies for the life sciences. The company's emphasis on research and development and collaboration with customers and partners distinguish it and ensure continuous growth and success. Answer: The Harvard Bioscience Inc is a global company specializing in selling scientific instruments and devices for the life sciences. They have three business segments: Life Science Research, Analytical Instruments, and Bioscience Tools. They offer a wide range of instruments for cell, tissue, and organ research. They also have instruments for analyzing biological samples and a portfolio of tools and consumables for the life sciences. They focus on high-quality products and comply with international standards. They sell their products worldwide through various channels and work closely with customers and partners. Continuous innovation and development are important to their growth strategy.

The expected revenue of Harvard Bioscience is 88.60 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Harvard Bioscience is -31.30 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Harvard Bioscience is currently -0.09. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Harvard Bioscience stock.

The price-to-sales ratio (P/S) of Harvard Bioscience is currently 0.03. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Harvard Bioscience stock.

The Eulerpool Quality Score for Harvard Bioscience is 1/10.

The ISIN of Harvard Bioscience is US4169061052. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Harvard Bioscience is 578107. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Harvard Bioscience is HBIO. The ticker symbol is used to trade Harvard Bioscience shares on the stock exchange.

Harvard Bioscience paid dividends every year for the past 0 years.

Harvard Bioscience is assigned to the 'Health' sector.

The dividends of Harvard Bioscience are distributed in USD.